568
Participants
Start Date
March 28, 2023
Primary Completion Date
May 7, 2024
Study Completion Date
May 7, 2024
ReMMi-D Digital Therapeutic
Evaluate the effectiveness and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.
Click Therapeutics, New York
Lead Sponsor
Click Therapeutics, Inc.
INDUSTRY